BioPharm International, March 2024

Despite a growing number of biosimilar approvals, market uptake remains a challenge.

The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.

Proprietary cell lines offer opportunities for achieving high AAV titers.

A tidal wave of questions floats the need for more upstream automation.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.

The license holder should negotiate, educate, contract, and then oversee the transportation contractor, says Siegfried Schmitt, vice president, Technical at Parexel.